| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $227,010 | 1 | 11 |
Sells | $904,576 | 8 | 89 |
| Morrison Briggs | director | 1 | $227,010 | 0 | $0 | $227,010 |
| Loomis David K | Chief Accounting Officer | 0 | $0 | 2 | $22,609 | $-22,609 |
| Saik Andrew | Chief Financial Officer | 0 | $0 | 1 | $43,377 | $-43,377 |
| Berkowitz Noah | Chief Medical Officer | 0 | $0 | 1 | $74,372 | $-74,372 |
| Cacace Angela M | Chief Scientific Officer | 0 | $0 | 2 | $89,585 | $-89,585 |
| Taylor Ian | President, R&D | 0 | $0 | 1 | $150,752 | $-150,752 |
| Houston John G | President and CEO | 0 | $0 | 1 | $523,881 | $-523,881 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Over the last 12 months, insiders at Arvinas, Inc. have bought $227,010 and sold $904,576 worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $10.11M and sold $28.58M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Morrison Briggs (director) — $227,010.
The last purchase of 30,000 shares for transaction amount of $227,010 was made by Morrison Briggs (director) on 2025‑09‑22.
| 2025-11-07 | Sale | Loomis David K | Chief Accounting Officer | 230 0.0003% | $9.89 | $2,275 | +25.17% | |
| 2025-09-22 | Morrison Briggs | director | 30,000 0.0411% | $7.57 | $227,010 | +30.08% | ||
| 2025-06-24 | Sale | Saik Andrew | Chief Financial Officer | 5,700 0.0077% | $7.61 | $43,377 | +2.71% | |
| 2025-06-17 | Sale | Cacace Angela M | Chief Scientific Officer | 2,583 0.0035% | $7.49 | $19,347 | +5.62% | |
| 2025-03-18 | Sale | Berkowitz Noah | Chief Medical Officer | 8,658 0.0128% | $8.59 | $74,372 | -7.48% | |
| 2025-02-24 | Sale | Houston John G | President and CEO | 31,338 0.0429% | $16.72 | $523,881 | -53.22% | |
| 2025-02-24 | Sale | Taylor Ian | President, R&D | 9,020 0.0123% | $16.71 | $150,752 | -53.22% | |
| 2025-02-24 | Sale | Cacace Angela M | Chief Scientific Officer | 4,207 0.0057% | $16.70 | $70,238 | -53.22% | |
| 2025-02-24 | Sale | Loomis David K | Chief Accounting Officer | 1,214 0.0017% | $16.75 | $20,335 | -53.22% | |
| 2024-11-07 | Sale | Loomis David K | Chief Accounting Officer | 231 0.0003% | $27.69 | $6,396 | -69.23% | |
| 2024-02-23 | Sale | Houston John G | President and CEO | 5,196 0.0095% | $47.05 | $244,472 | -44.89% | |
| 2024-02-23 | Sale | Cassidy Sean A | Chief Financial Officer | 1,702 0.0031% | $47.05 | $80,079 | -44.89% | |
| 2024-02-23 | Sale | Taylor Ian | Chief Scientific Officer | 1,701 0.0031% | $47.05 | $80,032 | -44.89% | |
| 2024-02-23 | Sale | Peck Ronald | Chief Medical Officer | 1,699 0.0031% | $47.05 | $79,938 | -44.89% | |
| 2023-11-08 | Sale | Loomis David K | Chief Accounting Officer | 229 0.0004% | $17.05 | $3,904 | +80.56% | |
| 2023-08-11 | Sale | Peck Ronald | Chief Medical Officer | 1,324 0.0024% | $24.39 | $32,289 | +20.32% | |
| 2023-03-01 | Sale | Houston John G | President and CEO | 5,878 0.0107% | $29.53 | $173,577 | -14.30% | |
| 2023-03-01 | Sale | Cassidy Sean A | Chief Financial Officer | 1,745 0.0032% | $29.53 | $51,530 | -14.30% | |
| 2023-03-01 | Sale | Taylor Ian | Chief Scientific Officer | 1,051 0.0019% | $29.53 | $31,036 | -14.30% | |
| 2022-08-12 | Sale | Peck Ronald | Chief Medical Officer | 1,258 0.0024% | $54.84 | $68,994 | -40.82% |
| Houston John G | President and CEO | 1157480 1.5933% | $14.28M | 1 | 11 | +24.92% |
| Saik Andrew | Chief Financial Officer | 164401 0.2263% | $2.03M | 0 | 1 | |
| Taylor Ian | President, R&D | 159121 0.219% | $1.96M | 1 | 13 | +66.46% |
| Cacace Angela M | Chief Scientific Officer | 154248 0.2123% | $1.9M | 0 | 2 | |
| Berkowitz Noah | Chief Medical Officer | 110023 0.1515% | $1.36M | 0 | 1 | |
| Morrison Briggs | director | 76021 0.1046% | $938,099.14 | 2 | 2 | |
| Loomis David K | Chief Accounting Officer | 31697 0.0436% | $391,140.98 | 0 | 4 | |
| RA CAPITAL MANAGEMENT, LLC | 3138412 4.3202% | $38.73M | 1 | 0 | +24.92% | |
| SHANNON TIMOTHY M | director | 1653128 2.2756% | $20.4M | 5 | 11 | +45.5% |
| Flynn James E | 10 percent owner | 411245 0.5661% | $5.07M | 1 | 0 | +24.92% |
| Loven Jakob | director | 312500 0.4302% | $3.86M | 1 | 0 | +24.92% |
| Ratcliffe Liam | director | 185686 0.2556% | $2.29M | 3 | 10 | +24.96% |
| Cassidy Sean A | Chief Financial Officer | 181916 0.2504% | $2.24M | 1 | 13 | +24.92% |
| 5AM VENTURES III, L.P. | 10 percent owner | 91162 0.1255% | $1.12M | 0 | 4 | |
| Peck Ronald | Chief Medical Officer | 67516 0.0929% | $833,147.44 | 0 | 8 | |
| Kennedy Edward Moore Jr. | director | 42718 0.0588% | $527,140.12 | 2 | 0 | +24.92% |
| Margus Bradley Albert | director | 2000 0.0028% | $24,680.00 | 1 | 5 | +24.92% |
$3,611,891 | 113 | 13.40% | $893.47M | |
$94,912,877 | 34 | -7.15% | $854.23M | |
$24,857,912 | 21 | -35.40% | $779.96M | |
$3,556,951 | 18 | 9.64% | $858.31M | |
$7,254,955 | 14 | 20.70% | $759M | |
$26,254,270 | 14 | 24.18% | $900.46M | |
Arvinas, Inc. (ARVN) | $133,809,976 | 13 | 31.29% | $896.44M |
$103,194,328 | 13 | 9.02% | $849.64M | |
$278,247,340 | 12 | 58.08% | $935.54M | |
$92,357,691 | 12 | 87.24% | $860.23M | |
$11,541,901 | 10 | 8.07% | $918.03M | |
$117,959,652 | 9 | -12.47% | $911M | |
$160,798,946 | 8 | -3.92% | $910.02M | |
$49,165,200 | 7 | 12.92% | $780.87M | |
$1,229,547 | 7 | 11.98% | $849.01M | |
$46,235,722 | 6 | -31.77% | $958.28M | |
$19,420,853 | 5 | 4.35% | $897.93M | |
$45,070 | 4 | 10.31% | $912.68M | |
$13,900 | 1 | -39.25% | $952.27M |
| Increased Positions | 105 | +40.38% | 13M | +19.33% |
| Decreased Positions | 112 | -43.08% | 17M | -24.61% |
| New Positions | 36 | New | 4M | New |
| Sold Out Positions | 40 | Sold Out | 4M | Sold Out |
| Total Postitions | 253 | -2.69% | 66M | -5.28% |
| Vanguard Group Inc | $107,700.00 | 13.38% | 8.56M | -831,929 | -8.86% | 2025-09-30 |
| Blackrock, Inc. | $85,581.00 | 10.63% | 6.8M | -86,514 | -1.26% | 2025-09-30 |
| Logos Global Management Lp | $70,134.00 | 8.71% | 5.58M | +2M | +68.94% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $42,107.00 | 5.23% | 3.35M | +1M | +55.63% | 2025-09-30 |
| Millennium Management Llc | $26,815.00 | 3.33% | 2.13M | +233,483 | +12.3% | 2025-09-30 |
| State Street Corp | $23,563.00 | 2.93% | 1.87M | +140,763 | +8.13% | 2025-09-30 |
| Geode Capital Management, Llc | $21,011.00 | 2.61% | 1.67M | +85,087 | +5.37% | 2025-09-30 |
| Morgan Stanley | $20,911.00 | 2.6% | 1.66M | +78,492 | +4.96% | 2025-09-30 |
| Tcg Crossover Management, Llc | $20,346.00 | 2.53% | 1.62M | +2M | New | 2025-09-30 |
| New Leaf Venture Partners, L.L.C. | $19,948.00 | 2.48% | 1.59M | 0 | 0% | 2025-09-30 |